AG-881

allosteric mutant IDH1/2 dual inhibitor

oral, brain penetrant, completed Ph. I in HV

from SBDD of prior mIDH inhibitor

ACS Med. Chem. Lett., 2020, 11, 101-107

Agios Pharmaceuticals, Cambridge, MA

AG-881 (vorasidenib) (Agios oral brain penetrant allosteric mutant IDH1/2 dual inhibitor clinical candidate)


 become a member to continue reading

Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.

  • Stay up-to-date and save more time with exclusive members-only content
  • On-board new team members with educational content and case studies
  • Generate ideas and discussion with easy-to-read slide decks
  • Generate ideas and discussion with easy-to-read slide decks